NCT01563536View on ClinicalTrials.gov

Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects

PHASE2CompletedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 29, 2012

Primary Completion Date

April 30, 2012

Study Completion Date

June 30, 2013

Conditions
Chronic Hepatitis C Infection
Interventions
DRUG

ABT-267

Tablet

DRUG

ABT-450

Tablet

DRUG

ABT-333

Tablet

DRUG

Ritonavir

Capsule

DRUG

Ribavirin

Tablet

Trial Locations (4)

12601

Site Reference ID/Investigator# 67385, Poughkeepsie

21401

Site Reference ID/Investigator# 67382, Annapolis

32809

Site Reference ID/Investigator# 67383, Orlando

93301

Site Reference ID/Investigator# 68002, Bakersfield

All Listed Sponsors
lead

AbbVie (prior sponsor, Abbott)

INDUSTRY

NCT01563536 - Study to Assess the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ABT-267 in HCV Infected Subjects | Biotech Hunter | Biotech Hunter